Ethical tradeoffs in trial design: Case study of an HPV vaccine trial in HIV-infected adolescent girls in lower income settings

Developing World Bioethics

Volumn 13, Issue 2, 2013, Pages 95-104

  Lindsey, J C ^a   Shah, S K ^b   Siberry, G K ^c   Jean Philippe, P ^d   Levin, M J ^e  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b Clinical Center Department of Bioethics   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Clinical trials; Public health; Research ethics; Standard of care; Vaccines

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN PAPILLOMAVIRUS;

VACCINE; WART VIRUS VACCINE;

ADOLESCENT; AIDS RELATED COMPLEX; ARTICLE; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); CROSSOVER PROCEDURE; DEVELOPING COUNTRY; ETHICS; FEMALE; HEALTH CARE QUALITY; HUMAN; METHODOLOGY; PAPILLOMAVIRUS INFECTION; POVERTY; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCIBILITY; RESEARCH ETHICS; RESEARCH SUBJECT;

CLINICAL TRIALS; PUBLIC HEALTH; RESEARCH ETHICS; STANDARD OF CARE; VACCINES;

ADOLESCENT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; CLINICAL TRIALS AS TOPIC; CONTROLLED CLINICAL TRIALS AS TOPIC; CROSS-OVER STUDIES; DEVELOPING COUNTRIES; ETHICS, RESEARCH; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; POVERTY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; RESEARCH SUBJECTS;

EID: 84880842815     PISSN: 14718731     EISSN: 14718847     Source Type: Journal    
DOI: 10.1111/dewb.12028     Document Type: Article

References (47)

1. E.M. Connor, R.S. Sperling, R. Gelber etal. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. NEJM 1994; 331: 1173-1180.
2. P. Lurie & S.M. Wolfe. Unethical trials of interventions to reduce perinatal transmission of the human immunodeficiency virus in developing countries. NEJM 1997; 337: 853-856.
3. J.S. Hawkins & E.J. Emanuel, ed. 2008. Exploitation and developing countries: The ethics of clinical research. Princeton, NJ: Princeton University Press.
4. R. Macklin. 2004. Double standards in medical research in developing countries. Cambridge: Cambridge University Press.
5. S. Philpott & U. Schuklenk. A Study that Should Not Have Been Done. Bioethics Forum, Hastings Center Report 2010; 41: 3, Available at: http://www.thehastingscenter.org/Bioethicsforum/Post.aspx?id=4626&bl ogid=140. [Accessed 14 Feb 2013].
6. E.J. Emanuel, D. Wendler & C. Grady. What makes clinical research ethical? JAMA 2000; 283: 2701-2711.
7. CDC. HPV Vaccine Information for Young Women - Fact Sheet (17 July 2012). Available at: http://www.cdc.gov/std/hpv/stdfact-hpv-vaccine-young-women.htm [Accessed 14 Feb 2013].
8. M.J. Abzug. Vaccination in the immunocompromised child: a probe of immune reconstitution. PIDJ 2009; 28: 233-236
9. G.K. Siberry, M.G. Warshaw, P.L. Williams, etal. Safety and immunogenicity of quadrivalent meningococcal conjugate vaccine in 2- to 10-year-old human immunodeficiency virus-infected children. PIDJ 2012; 31: 47-52
10. S.A. Madhi, P. Adrian, L. Kuwanda, etal. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunoedeficient virus infected and non-infected children in the absence of a booster dose of vaccine. Vaccine 2007; 25: 2451-2457
11. S.A. Madhi, L. Kuwanda, L. Saarinen, etal. Immunogenicity and effectiveness of Haemophilus influenzae type b conjugate vaccine in HIV infected and uninfected African children. Vaccine 2005; 23: 5517-5525
12. S.A. Madhi, K. Petersen, M. Khoosal, etal. Reduced effectiveness of Haemophilus influenzae type b conjugate vaccine in children with a high prevalence of human immunodeficiency virus type 1 infection. PIDJ 2002; 21: 315-321
13. M.L. Landrum, K.H. Hullsiek, A. Ganesan, etal. Hepatitis B vaccination and risk of hepatitis B infection in HIV-infected individuals. AIDS 2010; 24: 545-555.
14. World Medical Assocation. Declaration of Helsinki-Ethical Principles for Medical Research Involving Human Subjects. Oct 28, 2008. Available at: http://www.wma.net/en/30publications/10policies/b3/index.html.pdf?print- media-type&footer-right=[page]/[toPage] [Accessed 14 Feb 2013].
15. CIOMS. 2002 International ethical guidelines for biomedical research involving human subjects. Geneva, Switzerland, CIOMS.
16. C.M. Wheeler. Natural history of human papillomavirus infections, cytologic and histologic abnormalities, and cancer. Obstet Gynecol Clin North Am 2008; 35: 519-536.
17. J. Ferlay, H.R. Shin, F. Bray, etal. 2008. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer.
18. A.B. Moscicki, J.H. Ellenberg, P. Crowley-Nowick etal. Risk of high-grade squamous intraepithelial lesion in HIV-infected adolescents. JID 2004; 190: 1413-1421.
19. L.E. Markowitz, E.F. Dunne, M. Saraiya M, etal. Quadrivalent Human Papillomavirus vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2007; March 23: 56(RR-2): 1-24.
20. The Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. NEJM 2007; 356: 1915-1927.
21. B. Romanowski. Long term protection against cervical infection with the human papillomavirus: review of currently available vaccines. Hum Vaccin 2011; 7: 161-169.
22. S.A. Plotkin. Correlates of vaccine-induced immunity. CID 2008; 47: 401-409.
23. M.J. Levin, A.B. Moscicki, L.Y. Song, etal. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. JAIDS 2010; 55: 197-204.
24. B. Lu, A. Kumar, X. Castellsague etal. Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review and meta-analysis. BMC Infect Dis 2011; Jan 12: 11-13
25. N. Munoz, R. Manalastas Jr, P. Pitisuttithum etal. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised double-blind trial. Lancet 2009; 373: 1949-1957
26. H.C. Chen, M. Schiffman, C.Y. Lin etal. Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer. JNCI 2011; 103: 1387-1396.
27. CDC. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. MMWR 2007; 56 (No. RR-2).
28. Lurie & Wolfe, op. cit. note 2, pp. 853-856
29. D. Wendler, E.J. Emanuel & R.K. Lie. The standard of care debate: can research in developing countries be both ethical and responsive to those countries' health needs? AJPH 2004; 94: 923-928.
30. Hawkins & Emanuel, eds., op. cit. note 3.
31. R.K. Lie, E. Emanuel, C. Grady & D. Wendler. The standard of care debate: the Declaration of Helsinki versus the international consensus opinion. J Med Ethics 2004; 30: 190-193
32. A.A. Hyder & L. Dawson. Defining standard of care in the developing world: the intersection of international research ethics and health systems analysis. Developing World Bioethics 2005; 5: 142-152
33. A.J. London. Equipoise and international human-subjects research. Bioethics 2001; 15: 312-332.
34. Declaration of Helsinki-Ethical Principles for Medical Research Involving Human Subjects, op. cit. note 10.
35. CIOMS, note 11.
36. Lie, Emanuel, Grady etal., op. cit. note 25, pp. 923-928.
37. CIOMS, op. cit. note 11.
38. P.E. Cleaton-Jones. An ethical dilemma: availability of antiretroviral therapy after clinical trials with HIV-infected patients are ended. BMJ 1997; 314: 887-888.
39. Levin, Moscicki, Song etal., op. cit. note 19, pp. 197-204.
40. A. Weinberg, L.Y. Song, T. Fenton etal. Response to protective vaccines. Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 2012.
41. A.R. Kreimer, A.C. Rodriguez, A. Hildesheim, etal. Evaluation of the efficacy of fewer than three doses of a bivalent HPV 16/18 vaccine. Eurogin. Lisbon, Portugal, 2011.
42. K.M. Neuzil, do G. Canh, V.D. Thiem, etal. Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial. JAMA 2011; 305: 1424-1431.
43. Madhi, Petersen, Khoosal, etal., op. cit. note 9, pp. 315-321
44. Landrum, Hullsiek, Ganesan etal., op. cit. note 9, pp. 545-555; Advisory Committee on Immunization Practices. Updated recommendations for use of meningococcal conjugate vaccines. MMWR. 2011; 60: 72-76.
45. Advisory Committee on Immunization Practices. Updated recommendations for use of meningococcal conjugate vaccines. MMWR. 2011; 60: 72-76.
46. Neuzil, Canh, Thiem etal., op. cit. note 34, pp. 1424-1431.
47. R.E. Goodin. 1995. Utilitarianism as a public philosophy. Cambridge: Cambridge University Press.